Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas

Boaz Karmazyn, Mervyn D. Cohen, Samuel Gregory Jennings, Kent Robertson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: We observed bone marrow signal changes (BMSC) in patients with plexiform neurofibromas after treatment with imatinib mesylate (Gleevec). Objective: To evaluate the pattern and natural history of BMSC. Materials and methods The data were obtained from a pilot study of imatinib mesylate in patients with plexiform neurofibromas. All patients underwent baseline and sequential whole-body STIR 1.5-T MRI after treatment. The bone marrow signal on MRI was evaluated for abnormalities, location and pattern, and any change on follow-up studies. Results: The study group included 16 patients (8 males) with a median age of 14 years (range 4 to 25 years). The mean whole-body MRI follow-up duration was 1.9 years. Of the 16 patients, 14 (88%) developed BMSC. The signal change was asymmetrical in 9 of the 14 patients (64%). The appendicular skeleton was involved in all 14 patients and the axial skeleton in 3 patients (21%). BMSC was followed in 13 patients and decreased signal was seen in 9 patients (69%) after a mean duration of 1.3 years of treatment (range 0.6 to 2.9 years); no complications were observed. Conclusion: BMSC appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow-up, BMSC often showed a decrease without complications.

Original languageEnglish
Pages (from-to)1218-1222
Number of pages5
JournalPediatric Radiology
Volume42
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

Plexiform Neurofibroma
Neurofibromatosis 1
Young Adult
Bone Marrow
Skeleton
Imatinib Mesylate
Therapeutics
Natural History
Lower Extremity

Keywords

  • Bone marrow
  • MRI
  • Plexiform neurofibromatosis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pediatrics, Perinatology, and Child Health

Cite this

Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas. / Karmazyn, Boaz; Cohen, Mervyn D.; Jennings, Samuel Gregory; Robertson, Kent.

In: Pediatric Radiology, Vol. 42, No. 10, 10.2012, p. 1218-1222.

Research output: Contribution to journalArticle

@article{23655790a2c9479680dcc0650145d321,
title = "Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas",
abstract = "Background: We observed bone marrow signal changes (BMSC) in patients with plexiform neurofibromas after treatment with imatinib mesylate (Gleevec). Objective: To evaluate the pattern and natural history of BMSC. Materials and methods The data were obtained from a pilot study of imatinib mesylate in patients with plexiform neurofibromas. All patients underwent baseline and sequential whole-body STIR 1.5-T MRI after treatment. The bone marrow signal on MRI was evaluated for abnormalities, location and pattern, and any change on follow-up studies. Results: The study group included 16 patients (8 males) with a median age of 14 years (range 4 to 25 years). The mean whole-body MRI follow-up duration was 1.9 years. Of the 16 patients, 14 (88{\%}) developed BMSC. The signal change was asymmetrical in 9 of the 14 patients (64{\%}). The appendicular skeleton was involved in all 14 patients and the axial skeleton in 3 patients (21{\%}). BMSC was followed in 13 patients and decreased signal was seen in 9 patients (69{\%}) after a mean duration of 1.3 years of treatment (range 0.6 to 2.9 years); no complications were observed. Conclusion: BMSC appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow-up, BMSC often showed a decrease without complications.",
keywords = "Bone marrow, MRI, Plexiform neurofibromatosis",
author = "Boaz Karmazyn and Cohen, {Mervyn D.} and Jennings, {Samuel Gregory} and Kent Robertson",
year = "2012",
month = "10",
doi = "10.1007/s00247-012-2440-0",
language = "English",
volume = "42",
pages = "1218--1222",
journal = "Pediatric Radiology",
issn = "0301-0449",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Marrow signal changes observed in follow-up whole-body MRI studies in children and young adults with neurofibromatosis type 1 treated with imatinib mesylate (Gleevec) for plexiform neurofibromas

AU - Karmazyn, Boaz

AU - Cohen, Mervyn D.

AU - Jennings, Samuel Gregory

AU - Robertson, Kent

PY - 2012/10

Y1 - 2012/10

N2 - Background: We observed bone marrow signal changes (BMSC) in patients with plexiform neurofibromas after treatment with imatinib mesylate (Gleevec). Objective: To evaluate the pattern and natural history of BMSC. Materials and methods The data were obtained from a pilot study of imatinib mesylate in patients with plexiform neurofibromas. All patients underwent baseline and sequential whole-body STIR 1.5-T MRI after treatment. The bone marrow signal on MRI was evaluated for abnormalities, location and pattern, and any change on follow-up studies. Results: The study group included 16 patients (8 males) with a median age of 14 years (range 4 to 25 years). The mean whole-body MRI follow-up duration was 1.9 years. Of the 16 patients, 14 (88%) developed BMSC. The signal change was asymmetrical in 9 of the 14 patients (64%). The appendicular skeleton was involved in all 14 patients and the axial skeleton in 3 patients (21%). BMSC was followed in 13 patients and decreased signal was seen in 9 patients (69%) after a mean duration of 1.3 years of treatment (range 0.6 to 2.9 years); no complications were observed. Conclusion: BMSC appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow-up, BMSC often showed a decrease without complications.

AB - Background: We observed bone marrow signal changes (BMSC) in patients with plexiform neurofibromas after treatment with imatinib mesylate (Gleevec). Objective: To evaluate the pattern and natural history of BMSC. Materials and methods The data were obtained from a pilot study of imatinib mesylate in patients with plexiform neurofibromas. All patients underwent baseline and sequential whole-body STIR 1.5-T MRI after treatment. The bone marrow signal on MRI was evaluated for abnormalities, location and pattern, and any change on follow-up studies. Results: The study group included 16 patients (8 males) with a median age of 14 years (range 4 to 25 years). The mean whole-body MRI follow-up duration was 1.9 years. Of the 16 patients, 14 (88%) developed BMSC. The signal change was asymmetrical in 9 of the 14 patients (64%). The appendicular skeleton was involved in all 14 patients and the axial skeleton in 3 patients (21%). BMSC was followed in 13 patients and decreased signal was seen in 9 patients (69%) after a mean duration of 1.3 years of treatment (range 0.6 to 2.9 years); no complications were observed. Conclusion: BMSC appeared in most patients with neurofibromatosis type 1 following treatment with imatinib mesylate. BMSC was unusually asymmetrical and involved the lower extremities. On follow-up, BMSC often showed a decrease without complications.

KW - Bone marrow

KW - MRI

KW - Plexiform neurofibromatosis

UR - http://www.scopus.com/inward/record.url?scp=84867883342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867883342&partnerID=8YFLogxK

U2 - 10.1007/s00247-012-2440-0

DO - 10.1007/s00247-012-2440-0

M3 - Article

C2 - 22722872

AN - SCOPUS:84867883342

VL - 42

SP - 1218

EP - 1222

JO - Pediatric Radiology

JF - Pediatric Radiology

SN - 0301-0449

IS - 10

ER -